Jean-Yves Masson
Chercheur universitaire
Axe Oncologie
Publications
View all-
article Robu M, Shah RG, van den Heuvel D, Coulombe Y, Bazin M, van der Woude M, Kragten A, Lans H, Pascal JM, Masson JY, Luijsterburg MS, Shah GM
PARP1 and PARylation facilitate transcription-coupled DNA repair by stabilizing the CSB-RNAPII complex
Nucleic Acids Res 53 (22), 2025.
-
article Wang Y, Coulombe Y, Yueh WT, Conway GD, Milano L, Glass DJ, Thomas M, Rodrigue A, Nacson J, Lu D, Bernhardy AJ, Betsch RG, Russo AI, Elfar GA, Cai KQ, Testa JR, Andrake M, Dunbrack R, Gupta GP, Xia B, Dray E, Masson JY, Johnson N
PALB2 and 53BP1 govern post-resection homologous recombination DNA repair
Mol Cell 85 (21), 2025.
-
article Richardson ME, Bishop MFH, Holdren MA, de la Hoya M, Spurdle AB, Tavtigian SV, Brannan T, Young CC, Zec L, Hiraki S, Turnbull C, Tischkowitz M, Bernstein KA, Masson JY, McNulty SM, Pesaran T, Monteiro AN, Walker LC, Foulkes WD, Couch FJ
Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline PALB2 sequence variants
Am J Hum Genet 112 (10), 2025.
Projects
- Fonds de cancérologie et ses fonds liés, from 2005-04-01 to 2029-04-30
- Canada Research Chair in DNA repair and Cancer Therapeutics, from 2020-07-01 to 2027-06-30
- Réseau de recherche sur le cancer (RRCancer), from 2023-04-01 to 2026-03-31
- Tumor biobanking was supported by the Banque de tissus et de données en cancers solides of the Réseau de recherche sur le cancer (RRCancer)...The RRCancer is funded by the Oncopole...de l'Économie, de l'Innovation et de l'Énergie du Québec., from 2023-04-01 to 2026-03-31
- Emerging roles of Zinc Finger PAR-Interacting Proteins (ZIPPs) in DNA double-strand break (DSB) repair: implications in PARPi therapy, from 2024-04-01 to 2029-03-31
- Characterization of novel breast cancer susceptibility genes through large-scale targeted sequencing and functional assays., from 2024-04-01 to 2029-03-31
- Caractérisation de nouveaux gènes de susceptibilité au cancer du sein, from 2024-02-15 to 2027-03-31
- Roles of the tumor suppressor PALB2 at the intersection of DNA repair and synthetic lethal strategies in cancer, from 2024-10-01 to 2029-09-30
- Defining and targeting the eraser functions of Poly(ADP-ribose) Glycohydrolase (PARG) in PAR-DNA hybrids and DNA double-strand break repair, from 2025-07-01 to 2030-06-30
- Assays evaluating small molecule RAD51 inhibitors: the road to anti-RAD51 drugs to treat aggressive and drug-resistant breast cancer, from 2024-06-30 to 2026-06-29
- Defining the biological consequences of formaldehyde-induced DNA lesions, from 2025-04-01 to 2030-03-31
- Characterization of novel breast cancer susceptibility genes through large-scale targeted sequencing and functional assays, from 2025-04-01 to 2029-03-31
- Decoding the DNA double-strand break repair pathways: from mechanistic insights to human genome instability diseases, from 2018-07-01 to 2025-06-30
- Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II), from 2017-11-01 to 2025-09-30
- Investigating the Role of RECQL in Breast Cancer Susceptibility, from 2017-04-01 to 2024-03-31
- Poly(ADP-ribose) writers, readers, and erasers: Functions in DNA double-strand break repair and synthetic lethality, from 2019-10-01 to 2024-09-30
- Unveiling the roles of Poly(ADP)ribose Glycohydrolase (PARG) in DNA repair and cancer, from 2024-09-01 to 2025-08-31